Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
BIOD's Cash to Debt is ranked higher than
88% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. BIOD: No Debt )
BIOD' s 10-Year Cash to Debt Range
Min: 34.94   Max: No Debt
Current: No Debt

Interest Coverage No Debt
BIOD's Interest Coverage is ranked higher than
73% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIOD: No Debt )
BIOD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -4.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -59.38
BIOD's ROE (%) is ranked higher than
60% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. BIOD: -59.38 )
BIOD' s 10-Year ROE (%) Range
Min: -517.28   Max: -28.57
Current: -59.38

-517.28
-28.57
ROA (%) -46.99
BIOD's ROA (%) is ranked higher than
61% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. BIOD: -46.99 )
BIOD' s 10-Year ROA (%) Range
Min: -283.1   Max: -25.52
Current: -46.99

-283.1
-25.52
ROC (Joel Greenblatt) (%) -1997.38
BIOD's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. BIOD: -1997.38 )
BIOD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1997.38   Max: -484.98
Current: -1997.38

-1997.38
-484.98
EBITDA Growth (%) -42.30
BIOD's EBITDA Growth (%) is ranked higher than
55% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. BIOD: -42.30 )
BIOD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 51.6
Current: -42.3

0
51.6
EPS Growth (%) -42.00
BIOD's EPS Growth (%) is ranked higher than
57% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. BIOD: -42.00 )
BIOD' s 10-Year EPS Growth (%) Range
Min: -44   Max: 113.9
Current: -42

-44
113.9
» BIOD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BIOD Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

BIOD Guru Trades in Q4 2013

Chuck Royce 40,000 sh (New)
Jim Simons 145,500 sh (New)
» More
Q1 2014

BIOD Guru Trades in Q1 2014

Jim Simons 184,895 sh (+27.08%)
Chuck Royce 20,100 sh (-49.75%)
» More
Q2 2014

BIOD Guru Trades in Q2 2014

Jim Simons 225,653 sh (+22.04%)
Chuck Royce 20,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BIOD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.00
BIOD's P/B is ranked higher than
90% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. BIOD: 2.00 )
BIOD' s 10-Year P/B Range
Min: 0   Max: 3.3
Current: 2

0
3.3
EV-to-EBIT -0.59
BIOD's EV-to-EBIT is ranked higher than
76% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIOD: -0.59 )
BIOD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.59

Current Ratio 12.78
BIOD's Current Ratio is ranked higher than
92% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. BIOD: 12.78 )
BIOD' s 10-Year Current Ratio Range
Min: 0.82   Max: 25.41
Current: 12.78

0.82
25.41
Quick Ratio 12.78
BIOD's Quick Ratio is ranked higher than
92% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. BIOD: 12.78 )
BIOD' s 10-Year Quick Ratio Range
Min: 0.82   Max: 25.41
Current: 12.78

0.82
25.41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.04
BIOD's Price/Net Cash is ranked higher than
98% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. BIOD: 2.04 )
BIOD' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 7.14
Current: 2.04

0.61
7.14
Price/Net Current Asset Value 2.01
BIOD's Price/Net Current Asset Value is ranked higher than
98% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. BIOD: 2.01 )
BIOD' s 10-Year Price/Net Current Asset Value Range
Min: 0.61   Max: 7.14
Current: 2.01

0.61
7.14
Price/Tangible Book 1.91
BIOD's Price/Tangible Book is ranked higher than
94% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. BIOD: 1.91 )
BIOD' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 6.82
Current: 1.91

0.56
6.82
Earnings Yield (Greenblatt) 2311.10
BIOD's Earnings Yield (Greenblatt) is ranked higher than
99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. BIOD: 2311.10 )
BIOD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 5045.8
Current: 2311.1

0
5045.8
Forward Rate of Return (Yacktman) -183.97
BIOD's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. BIOD: -183.97 )
BIOD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -183.97

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BDQN.Germany
Biodel, Inc., was incorporated in the State of Delaware on December 3, 2003 and commenced operations in January 2004. Biodel is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that might be safer, more effective and more convenient for patients. The Company develops its product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. Its most advanced program involves developing proprietary formulations of injectable recombinant human insulin, or RHI, designed to be more rapid-acting than the 'rapid-acting' mealtime insulin analogs currently used to treat patients with Type 1 and Type 2 diabetes. The Company, therefore, refers to these formulations as its 'ultra-rapid-acting' insulin formulations. In addition to the RHI-based formulations, the Company is using its formulation technologies to develop new ultra-rapid-acting formulations of insulin analogs. In addition to its ultra-rapid-acting insulin formulation program, the Company is developing a liquid glucagon formulation for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products.
» More Articles for BIOD

Headlines

Articles On GuruFocus.com
cooldecency99 note on BIOD May 01 2010 
Biodel Reports Third Quarter Fiscal Year 2009 Financial Results Aug 07 2009 
Biodel to Report Third Quarter Fiscal Year 2009 Results on August 7, 2009 Aug 03 2009 
Biodel Reports First Quarter Fiscal Year 2009 Financial Results and Clinical Update Feb 05 2009 
Biodel to Report First Quarter Fiscal Year 2009 Results and Top Line Results of Bioequivalence Study Jan 30 2009 
Biodel Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results Dec 10 2008 

More From Other Websites
Nasdaq stocks posting largest volume increases Aug 28 2014
BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Aug 27 2014
Biodel Appoints Gary G. Gemignani as Chief Financial Officer Aug 25 2014
Biodel Appoints Gary G. Gemignani as Chief Financial Officer Aug 25 2014
BIODEL INC Financials Aug 22 2014
Biodel Q3 Loss Narrower than Expected, Gives Pipeline Update Aug 14 2014
BIODEL INC Files SEC form 10-Q, Quarterly Report Aug 13 2014
[video] Stocks Close Higher, But Off Day's Highs Aug 11 2014
BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 11 2014
Biodel Reports Third Quarter Fiscal Year 2014 Financial Results Aug 11 2014
Biodel's insulin drug found effective in trial Aug 11 2014
Q3 2014 BIODEL INC Earnings Release - 4:00 pm ET Aug 11 2014
Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Glucose Control Following Standardized... Aug 11 2014
Biodel to Present at the Wedbush PacGrow Life Sciences Management Access Conference Aug 06 2014
Biodel to Report Third Quarter Fiscal Year 2014 Financial Results on August 11, 2014 Aug 05 2014
Biodel Enters Into $15 Million Equity Commitment With Lincoln Park Capital Jul 28 2014
Biodel to Present at the JMP Securities Healthcare Conference Jun 11 2014
Biodel to Present Data on Ultra-Rapid-Acting Insulin and Glucagon Product Candidates at 2014... Jun 10 2014
BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers May 23 2014
Biodel Q2 Loss Wider Than Expected May 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK